Nagayama, Aiko
Ellisen, Leif W.
Chabner, Bruce
Bardia, Aditya
Funding for this research was provided by:
National Institutes of Health (K12CA087723–14)
Article History
First Online: 8 November 2017
Compliance with Ethical Standards
:
: A. Bardia was supported by the US National Institutes of Health (NIH) (K12CA087723–14).
: Aiko Nagayama owns stock options in Chugai, Inc., and a family member has a leadership position with Chugai, Inc. and Roche, Inc. Bruce Chabner owns stocks in Seattle Genetics. Aditya Bardia has received consulting fees or honorarium by Genentech, Pfizer, and Novartis. Leif Ellisen declares no conflict of interest.